Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Thousand Oaks Biologics, GeneQuantum Partner for ADC Drug Development | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Thousand Oaks Biologics, GeneQuantum Partner for ADC Drug Development

GQ will leverage TOBio's expertise in CMC and commercial manufacturing.

By: Anthony Vecchione

Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. (GQ) entered into a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

The over 200 million RMB collaboration will allow GQ to leverage TOBio’s expertise in CMC and commercial manufacturing to advance its pharmaceutical research on ADC products and enable GQ to speed up its Biologics License Applications. Meanwhile, GQ will share with TOBio its leading enzymatic site-specific conjugation technology to provide more effective and comprehensive CDMO services to the industry.

“We are thrilled to have reached an in-depth collaboration with Thousand Oaks Biologics,” said Qin Gang, chairman of GQ. “TOBio is a cutting-edge global biopharmaceutical development and manufacturing organization, whose CMC capabilities in biologics are widely acknowledged. GQ and TOBio will collaborate closely, leveraging our respective strengths and resources, to pursue multiple cooperative projects, and to jointly accelerate the development of the ADC industry.”

Luo Shun, chairman of TOBio said, “I am very excited to establish this collaboration with GeneQuantum Healthcare. GQ’s innovative conjugation technology offers significant value and differentiated advantages in the discovery and development of ADC molecules. We believe Thousand Oaks Biologics’ competitive CMC expertise in large molecules will fully empower GeneQuantum to accelerate its product development process, making high-quality biological drugs accessible and affordable to patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics